Congress

“Less is more” in medication-overuse headache

6668 2484 Peter Stevenson, PhD

Monitoring, recognition and effective patient education are cornerstones in the diagnosis and prevention of medication-overuse headache (MOH), delegates heard at the 5th Annual Congress of the European Academy of Neurology…

read more

Treating nature with NURTURE: Interim results of nusinersen for SMA

3473 2300 Mea Holm, PhD

Promising results for a disease-modifying treatment for spinal muscular atrophy (SMA) were presented at the 5th Annual Congress of the European Academy of Neurology (EAN) in Oslo, Norway, last week.…

read more

Natalizumab treatment associated with reduction of gliotic biomarkers in white matter

3067 2300 Michael Furrer, PhD

New data on the effect of natalizumab treatment on neuronal and membrane integrity in lesional white matter were presented at the recent 5th Annual Congress of the European Academy of…

read more

Serum NfL levels shine a light on neuroaxonal damage and disease

4089 2300 Michael Furrer, PhD

The 5th Annual Congress of the European Academy of Neurology (EAN) in Oslo, Norway, featured an in-depth exploration of the role of neurofilament light chain (NfL) protein levels as a…

read more

Cellular power failures linked to Parkinsonism

3150 2100 Mea Holm, PhD

Mounting evidence is linking neurodegenerative disorders, such as Parkinsonism and dementia, with mitochondrial dysfunction.1 At the 5th Annual Congress of the European Academy of Neurology (EAN) in Oslo, Norway, the…

read more

8-year follow-up data of alemtuzumab presented

1920 1280 Michael Furrer, PhD

An update of the long-term efficacy and safety data of alemtuzumab in patients with relapsing-remitting MS was presented at the 5th Annual Congress of the European Academy of Neurology (EAN)…

read more
news

News from the ocrelizumab front

3300 2200 Carlotta Foletti, PhD

In our ongoing coverage of the AAN Annual Meeting in Philadelphia, we are focusing on select posters reporting on studies of ocrelizumab, an intravenous humanised monoclonal antibody that selectively targets…

read more
Doctor

Latest advances in migraine therapy

3682 2200 Carlotta Foletti, PhD

Migraines are the most common type of primary headache disorders, and triptans – serotonin 5-HT1B/1D receptor agonists originally developed as cranial vasoconstrictors – are the backbone of current acute attack…

read more

Preventing migraines through diet

1920 1080 Carlotta Foletti, PhD

As part of our coverage on the updates in migraine research at the 2019 AAN Annual Meeting, we attended Dr Belinda Savage-Edwards’ presentation – in collaboration with chef Tess Connors…

read more
Brainwork is supported by unrestricted grants from: